skip to main content
Idioma:
Primo Advanced Search
Primo Advanced Search Query Term
Primo Advanced Search Query Term
Primo Advanced Search Query Term
Primo Advanced Search prefilters
Busca Simples
previous page 3 4 Resultados 5 6 7 next page
Result Number Material Type Add to My Shelf Action Record Details and Options
41
Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis
Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis
Material Type:
Artigo 		Adicionar ao Meu Espaço

Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis

KHOURY, H. J ; KUKREJA, M ; GALE, R. P ; MARKS, D. I ; MCCARTHY, P. L ; WOOLFREY, A ; SZER, J ; GIRALT, S. A ; MAZIARZ, R. T ; CORTES, J ; HOROWITZ, M. M ; LEE, S. J ; GOLDMAN, J. M ; WANG, T ; HALTER, J ; ARORA, M ; GUPTA, V ; RIZZIERI, D. A ; GEORGE, B ; KEATING, A

Bone marrow transplantation (Basingstoke), 2012-06, Vol.47 (6), p.810-816 [Periódico revisado por pares]

Basingstoke: Nature Publishing Group

Texto completo disponível

Citações Citado por
42
How to make the problem of divine hiddenness worse
How to make the problem of divine hiddenness worse
Material Type:
Artigo 		Adicionar ao Meu Espaço

How to make the problem of divine hiddenness worse

Rizzieri, Aaron

International journal for philosophy of religion, 2021-08, Vol.90 (1), p.3-17 [Periódico revisado por pares]

Dordrecht: Springer Netherlands

Texto completo disponível

Citações Citado por
43
Contractualism, exclusionary reasons and the moral argument for theism
Contractualism, exclusionary reasons and the moral argument for theism
Material Type:
Artigo 		Adicionar ao Meu Espaço

Contractualism, exclusionary reasons and the moral argument for theism

Rizzieri, Aaron

Religious studies, 2023-03, Vol.59 (1), p.18-33 [Periódico revisado por pares]

Cambridge, UK: Cambridge University Press

Texto completo disponível

Citações Citado por
44
Pre-engraftment syndrome after myeloablative dual umbilical cord blood transplantation: risk factors and response to treatment
Pre-engraftment syndrome after myeloablative dual umbilical cord blood transplantation: risk factors and response to treatment
Material Type:
Artigo 		Adicionar ao Meu Espaço

Pre-engraftment syndrome after myeloablative dual umbilical cord blood transplantation: risk factors and response to treatment

KANDA, J ; KAYNAR, L ; GASPARETTO, C ; CHUTE, J. P ; MORRIS, A ; WINKEL, S ; MCPHERSON, J ; KURTZBERG, J ; CHAO, N. J ; HORWITZ, M. E ; KANDA, Y ; PRASAD, V. K ; PARIKH, S. H ; LAN, L ; SHEN, T ; RIZZIERI, D. A ; LONG, G. D ; SULLIVAN, K. M

Bone marrow transplantation (Basingstoke), 2013-07, Vol.48 (7), p.926-931 [Periódico revisado por pares]

Basingstoke: Nature Publishing Group

Texto completo disponível

Citações Citado por
45
Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial
Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial

ARMAND, Philippe ; NAGLER, Arnon ; FAY, Joseph W ; RIZZIERI, David A ; HOSING, Chitra M ; BALL, Edward D ; UBERTI, Joseph P ; LAZARUS, Hillard M ; MAPARA, Markus Y ; GREGORY, Stephanie A ; TIMMERMAN, John M ; ANDORSKY, David ; WELLER, Edie A ; OR, Reuven ; WALLER, Edmund K ; ROTEM-YEHUDAR, Rinat ; GORDON, Leo I ; DEVINE, Steven M ; AVIGAN, David E ; CHEN, Yi-Bin ; KAMINSKI, Mark S ; KENT HOLLAND, H ; WINTER, Jane N ; MASON, James R

Journal of clinical oncology, 2013-11, Vol.31 (33), p.4199-4206 [Periódico revisado por pares]

Alexandria, VA: American Society of Clinical Oncology

Texto completo disponível

Citações Citado por
46
A Phase 2 Clinical Trial of Deforolimus (AP23573, MK-8669), a Novel Mammalian Target of Rapamycin Inhibitor, in Patients with Relapsed or Refractory Hematologic Malignancies
A Phase 2 Clinical Trial of Deforolimus (AP23573, MK-8669), a Novel Mammalian Target of Rapamycin Inhibitor, in Patients with Relapsed or Refractory Hematologic Malignancies
Material Type:
Artigo 		Adicionar ao Meu Espaço

A Phase 2 Clinical Trial of Deforolimus (AP23573, MK-8669), a Novel Mammalian Target of Rapamycin Inhibitor, in Patients with Relapsed or Refractory Hematologic Malignancies

Rizzieri, David A ; Feldman, Eric ; Dipersio, John F ; Gabrail, Nashat ; Stock, Wendy ; Strair, Roger ; Rivera, Victor M ; Albitar, Maher ; Bedrosian, Camille L ; Giles, Francis J

Clinical cancer research, 2008-05, Vol.14 (9), p.2756-2762 [Periódico revisado por pares]

United States: American Association for Cancer Research

Texto completo disponível

Citações Citado por
47
Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study
Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study
Material Type:
Artigo 		Adicionar ao Meu Espaço

Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study

Issa, Jean-Pierre J, Prof ; Roboz, Gail, Prof ; Rizzieri, David, Prof ; Jabbour, Elias, MD ; Stock, Wendy, Prof ; O'Connell, Casey, MD ; Yee, Karen, MD ; Tibes, Raoul, MD ; Griffiths, Elizabeth A, MD ; Walsh, Katherine, MD ; Daver, Naval, MD ; Chung, Woonbok, PhD ; Naim, Sue, BS ; Taverna, Pietro, PhD ; Oganesian, Aram, PhD ; Hao, Yong, MD ; Lowder, James N, MD ; Azab, Mohammad, MD ; Kantarjian, Hagop, Prof

The lancet oncology, 2015-09, Vol.16 (9), p.1099-1110 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
48
Use of tamibarotene, a potent and selective RARα agonist, in combination with azacitidine in patients with relapsed and refractory AML with RARA gene overexpression
Use of tamibarotene, a potent and selective RARα agonist, in combination with azacitidine in patients with relapsed and refractory AML with RARA gene overexpression
Material Type:
Artigo 		Adicionar ao Meu Espaço

Use of tamibarotene, a potent and selective RARα agonist, in combination with azacitidine in patients with relapsed and refractory AML with RARA gene overexpression

Stein, Eytan M ; de Botton, Stephane ; Cluzeau, Thomas ; Pigneux, Arnaud ; Liesveld, Jane L ; Cook, Rachel J ; Rousselot, Philippe ; Rizzieri, David A ; Braun, Thorsten ; Roboz, Gail J ; Lebon, Delphine ; Heiblig, Mael ; Baker, Kristen ; Volkert, Angela ; Paul, Sofia ; Rajagopal, Nisha ; Roth, David A ; Kelly, Michael ; Peterlin, Pierre

Leukemia & lymphoma, 2023-12, Vol.64 (12), p.1992-2001 [Periódico revisado por pares]

United States: Taylor & Francis

Texto completo disponível

Citações Citado por
49
The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia, stem cells
The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia, stem cells
Material Type:
Artigo 		Adicionar ao Meu Espaço

The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia, stem cells

JORDAN, C. T ; UPCHURCH, D ; LUGER, S. M ; PHILLIPS, G. L ; SZILVASSY, S. J ; GUZMAN, M. L ; HOWARD, D. S ; PETTIGREW, A. L ; MEYERROSE, T ; ROSSI, R ; GRIMES, B ; RIZZIERI, D. A

Leukemia, 2000-10, Vol.14 (10), p.1777-1784 [Periódico revisado por pares]

London: Nature Publishing

Texto completo disponível

Citações Citado por
50
Preemptive dosing of plerixafor given to poor stem cell mobilizers on day 5 of G-CSF administration
Preemptive dosing of plerixafor given to poor stem cell mobilizers on day 5 of G-CSF administration
Material Type:
Artigo 		Adicionar ao Meu Espaço

Preemptive dosing of plerixafor given to poor stem cell mobilizers on day 5 of G-CSF administration

HORWITZ, M. E ; CHUTE, J. P ; GASPARETTO, C ; LONG, G. D ; MCDONALD, C ; MORRIS, A ; RIZZIERI, D. A ; SULLIVAN, K. M ; CHAO, N. J

Bone marrow transplantation (Basingstoke), 2012-08, Vol.47 (8), p.1051-1055 [Periódico revisado por pares]

Basingstoke: Nature Publishing Group

Texto completo disponível

Citações Citado por
previous page 3 4 Resultados 5 6 7 next page

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

Refinar Meus Resultados

Tipo de Recurso 

  1. Artigos  (4.588)
  2. Newsletter Articles  (53)
  3. Livros  (36)
  4. Book Chapters  (28)
  5. Verbetes  (22)
  6. magazinearticle  (14)
  7. Produções Acadêmicas  (10)
  8. Reports  (7)
  9. Recursos Textuais  (6)
  10. Resenhas  (4)
  11. Outros  (3)
  12. Imagens  (1)
  13. Mais opções open sub menu

Data de Publicação 

De até
Refinar
  1. Antes de1983  (18)
  2. 1983Até1992  (230)
  3. 1993Até2002  (446)
  4. 2003Até2013  (1.810)
  5. Após 2013  (2.273)
  6. Mais opções open sub menu

Idioma 

  1. Inglês  (4.086)
  2. Português  (670)
  3. Japonês  (541)
  4. Espanhol  (29)
  5. Francês  (21)
  6. Alemão  (9)
  7. Polonês  (4)
  8. Russo  (1)
  9. Vários idiomas  (1)
  10. Norueguês  (1)
  11. Chinês  (1)
  12. Indeterminado  (1)
  13. Mais opções open sub menu

Novas Pesquisas Sugeridas

Ignorar minha busca e procurar por tudo

Deste Autor:

  1. Rizzieri, J
  2. Luque, C
  3. Montoro Filho, A
  4. Amaral, C
  5. Lopes, L

Neste Assunto:

  1. Science & Technology
  2. Life Sciences & Biomedicine
  3. Humans
  4. Oncology
  5. Hematology

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.